HHS Secretary Favors Regenerative Medicine Over Traditional Pharma: Blessing And Curse?

 
• By Sarah Karlin-Smith

Cell and gene therapy developers may not have to contend with HHS Secretary Robert F. Kennedy Jr.’s animosity like the traditional pharma industry, but his disinterest in distinguishing between the good and bad actors in the space could backfire.

CMS Administrator Mehmet Oz, HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Martin Makary.
HHS Secretary Robert F. Kennedy Jr. (center) wants the US to invest in the cell and gene therapy space, but his vision for the field may not be aligned with many biopharma industry stakeholders. (Screenshot of FDA webstream.)

More from Cell & Gene Therapies

More from Geography